3D Cell-SELEX: Development of RNA aptamers as molecular probes for PC-3 tumor cell line

Experimental Cell Research

Volumn 341, Issue 2, 2016, Pages 147-156

  Souza, Aline G ^a   Marangoni, Karina ^a,b   Fujimura, Patrícia T ^a   Alves, Patrícia T ^a   Silva, Márcio J ^b   Bastos, Victor Alexandre F ^a   Goulart, Luiz R ^a,c   Goulart, Vivian A ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3D cell culture; Cell SELEX; Prostate cancer; RNA aptamers

Indexed keywords

A4 APTAMER; APTAMER; LIGAND; UNCLASSIFIED DRUG; MOLECULAR PROBE;

3D CELL SELEX; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL STRUCTURE; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DISSOCIATION CONSTANT; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR PROBE; PRIORITY JOURNAL; PROSTATE TUMOR; RNA FOLDING; RNA SEQUENCE; RNA STABILITY; SEQUENCE ANALYSIS; SPHEROID CELL; SUPERNATANT; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; CELL CULTURE TECHNIQUE; CHEMISTRY; CONFORMATION; GENETICS; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PROCEDURES;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; HUMANS; LIGANDS; MALE; MOLECULAR PROBES; NUCLEIC ACID CONFORMATION; PROSTATIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84958832313     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2016.01.015     Document Type: Article

References (45)

1. Lee E.-K., Cho H., Kim C.-W. Proteomic analysis of cancer stem cells in human prostate cancer cells. Biochem. Biophys. Res. Commun. 2011, 412:279-285. 10.1016/j.bbrc.2011.07.083.
2. Zadra G., Photopoulos C., Loda M. The fat side of prostate cancer. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 2013, 1831:1518-1532. 10.1016/j.bbalip.2013.03.010.
3. Yardy G., McGregor S., Bodmer W. The molecular staging of prostate cancer. BJU Int. 2005, 95:907. 10.1111/j.1464-410X.2005.05494.x.
4. Li Z., Cui Z. Three-dimensional perfused cell culture. Biotechnol. Adv. 2014, 32:243-254. 10.1016/j.biotechadv.2013.10.006.
5. Souza G.R., Molina J.R., Raphael R.M., Ozawa M.G., Stark D.J., Levin C.S., et al. Three-dimensional tissue culture based on magnetic cell levitation. Nat. Nanotechnol. 2010, 5:291-296. 10.1038/nnano.2010.23.
6. Timm D.M., Chen J., Sing D., a Gage J., Haisler W.L., Neeley S.K., et al. A high-throughput three-dimensional cell migration assay for toxicity screening with mobile device-based macroscopic image analysis. Sci. Rep. 2013, 3:3000. 10.1038/srep03000.
7. Haisler W.L., Timm D.M., a Gage J., Tseng H., Killian T.C., Souza G.R. Three-dimensional cell culturing by magnetic levitation. Nat. Protoc. 2013, 8:1940-1949. 10.1038/nprot.2013.125.
8. Tanner K., Gottesman M.M. Beyond 3D culture models of cancer. Sci. Transl. Med. 2015, 7:7-10.
9. Thoma C.R., Zimmermann M., Agarkova I., Kelm J.M., Krek W. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv. Drug Deliv. Rev. 2014, 69-70:29-41. 10.1016/j.addr.2014.03.001.
10. Breslin S., O'Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. Drug Discov. Today 2013, 18:240-249. 10.1016/j.drudis.2012.10.003.
11. Windus L.C.E., Kiss D.L., Glover T., Avery V.M. In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer. Exp. Cell Res. 2012, 318:2507-2519. 10.1016/j.yexcr.2012.07.013.
12. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822. 10.1038/346183a0.
13. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510. 10.1126/science.2200121.
14. Guo K.T., Paul A., Schichor C., Ziemer G., Wendel H.P. Cell-SELEX: novel perspectives of aptamer-based therapeutics. Int. J. Mol. Sci. 2008, 9:668-678. 10.3390/ijms9040668.
15. Sefah K., Shangguan D., Xiong X., O'Donoghue M.B., Tan W. Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 2010, 5:1169-1185. 10.1038/nprot.2010.66.
16. Ohuchi S. Cell-SELEX technology. Biores. Open Access 2012, 1:265-272. 10.1089/biores.2012.0253.
17. Zhang Y., Chen Y., Han D., Ocsoy I., Tan W. Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis 2010, 2:907-918. 10.4155/bio.10.46.Aptamers.
18. Marangoni K., Neves A.F., Rocha R.M., Faria P.R., Alves P.T., Souza A.G., et al. Prostate-specific RNA aptamer: promising nucleic acid antibody-like cancer detection. Sci. Rep. 2015, 5:12090. 10.1038/srep12090.
19. Singer B.S., Shtatland T., Brown D., Gold L. Libraries for genomic SELEX. Nucleic Acids Res. 1997, 25:781-786. 10.1093/nar/25.4.781.
20. Wang Y., Luo Y., Bing T., Chen Z., Lu M., Zhang N., et al. DNA aptamer evolved by cell-SELEX for recognition of prostate cancer. PLoS One 2014, 9:1-10. 10.1371/journal.pone.0100243.
21. Chang Y.M., Donovan M.J., Tan W. Using aptamers for cancer biomarker discovery. J. Nucleic Acids 2013, 2013. 10.1155/2013/817350.
22. Jaganathan H., Gage J., Leonard F., Srinivasan S., Souza G.R., Dave B., et al. Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation. Sci. Rep. 2014, 4:6468. 10.1038/srep06468.
23. Germer K., Leonard M., Zhang X. RNA aptamers and their therapeutic and diagnostic applications. Int. J. Biochem. Mol. Biol. 2013, 4:27-40.
24. Thiel K.W., Giangrande P.H. Intracellular delivery of RNA-based therapeutics using aptamers. Ther. Deliv. 2010, 1:849-861. 10.4155/tde.10.61.
25. Dua P., Kim S., Lee D.K. Nucleic acid aptamers targeting cell-surface proteins. Methods 2011, 54:215-225. 10.1016/j.ymeth.2011.02.002.
26. Ghosh D., Beavis R.C., Wilkins J.a The identification and characterization of membranome components. J. Proteome Res. 2008, 7:1572-1583. 10.1021/pr070509u.
27. T. Cavalier-Smith, Membranome and membrane heredity in development and evolution," in Organelles Genomes and Eukaryote Phylogeny an Evolutionary Synthesis in the Age of Genomics, 2012, doi: 10.1201/9780203508930.
28. Sefah K., Meng L., Lopez-Colon D., Jimenez E., Liu C., Tan W. DNA aptamers as molecular probes for colorectal cancer study. PLoS One 2010, 5:1-14. 10.1371/journal.pone.0014269.
29. Kang D., Wang J., Zhang W., Song Y., Li X., Zou Y., et al. Selection of DNA aptamers against glioblastoma cells with high affinity and specificity. PLoS One 2012, 7:1-9. 10.1371/journal.pone.0042731.
30. Choi K.H., Park M.W., Lee S.Y., Jeon M.-Y., Kim M.Y., Lee H.K., et al. Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer. Mol. Cancer Ther. 2006, 5:2428-2434. 10.1158/1535-7163.MCT-05-0204.
31. Zhang X., Zhang J., Ma Y., Pei X., Liu Q., Lu B., et al. A cell-based single-stranded DNA aptamer specifically targets gastric cancer. Int. J. Biochem. Cell Biol. 2014, 46:1-8. 10.1016/j.biocel.2013.10.006.
32. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24:1005-1015. 10.1038/nbt1223.
33. Li N., Nguyen H.H., Byrom M., Ellington A.D. Inhibition of cell proliferation by an anti-egfr aptamer. PLoS One 2011, 6:1-10. 10.1371/journal.pone.0020299.
34. Liu Y., Kuan C.-T., Mi J., Zhang X., Clary B.M., D.B.D., et al. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane- bound EGFRvIII and induce apoptosis. Biol Chem. 2009, 390:137-144. 10.1016/j.biotechadv.2011.08.021.Secreted.
35. Zhou J., Li H., Li S., Zaia J., Rossi J.J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 2008, 16:1481-1489. 10.1038/mt.2008.92.Novel.
36. Santulli-marotto S., Nair S.K., Rusconi C., Sullenger B., Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 2004, 1:7483-7489.
37. A. Rentmeister, A. Bill, T. Wahle, J. Walter, M. Famulok, RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of β -secretase BACE1 in vitro, 2006, pp. 1650-1660, doi: 10.1261/rna.126306.BACE.
38. Li N., Ebright J.N., Stovall G.M., Chen X., Nguyen H.H., Singh A., et al. Technical and biological issues relevant to cell typing with aptamers. J. Proteome Res. 2009, 8:2438-2448. 10.1021/pr801048z.
39. Huang D.-B., Vu D., a Cassiday L., Zimmerman J.M., Maher L.J., Ghosh G. Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA aptamer. Proc. Natl. Acad. Sci. USA 2003, 100:9268-9273. 10.1073/pnas.1632011100.
40. Lee H.K., Choi Y.S., Park Y.A., Jeong S. Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells. Cancer Res. 2006, 66:10560-10566. 10.1158/0008-5472.CAN-06-2526.
41. Bardeesy N., Pelletier J. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. Nucleic Acids Res. 1998, 26:1784-1792.
42. Shigdar S., Qiao L., Zhou S.-F., Xiang D., Wang T., Li Y., et al. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013, 330:84-95. 10.1016/j.canlet.2012.11.032.
43. Ohuchi S.P., Ohtsu T., Nakamura Y. Selection of RNA aptamers against recombinant transforming growth factor-β type III receptor displayed on cell surface. Biochimie 2006, 88:897-904. 10.1016/j.biochi.2006.02.004.
44. Leea J.B., Sonb S.H., Parkb M.C., Kima T.H., Kima M.G., Yooa S.D., et al. A novel in vitro permeability assay using three-dimensional cell culture system. J. Biotechnol. 2015, 10.1016/j.jbiotec.2014.12.019.
45. Chushak Y., Stone M.O. In silico selection of RNA aptamers. Nucleic Acids Res. 2009, 37:1-9. 10.1093/nar/gkp408.